TWI619498B - 精神分裂症的處置方法 - Google Patents

精神分裂症的處置方法 Download PDF

Info

Publication number
TWI619498B
TWI619498B TW106134526A TW106134526A TWI619498B TW I619498 B TWI619498 B TW I619498B TW 106134526 A TW106134526 A TW 106134526A TW 106134526 A TW106134526 A TW 106134526A TW I619498 B TWI619498 B TW I619498B
Authority
TW
Taiwan
Prior art keywords
carbon
low
compound
alkyl
group
Prior art date
Application number
TW106134526A
Other languages
English (en)
Chinese (zh)
Other versions
TW201808302A (zh
Inventor
上野隆司
Original Assignee
蘇坎波公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 蘇坎波公司 filed Critical 蘇坎波公司
Publication of TW201808302A publication Critical patent/TW201808302A/zh
Application granted granted Critical
Publication of TWI619498B publication Critical patent/TWI619498B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW106134526A 2011-08-05 2012-08-03 精神分裂症的處置方法 TWI619498B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515418P 2011-08-05 2011-08-05
US61/515,418 2011-08-05

Publications (2)

Publication Number Publication Date
TW201808302A TW201808302A (zh) 2018-03-16
TWI619498B true TWI619498B (zh) 2018-04-01

Family

ID=47627335

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106134526A TWI619498B (zh) 2011-08-05 2012-08-03 精神分裂症的處置方法
TW101127939A TWI619497B (zh) 2011-08-05 2012-08-03 精神分裂症的處置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW101127939A TWI619497B (zh) 2011-08-05 2012-08-03 精神分裂症的處置方法

Country Status (18)

Country Link
US (2) US8592483B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739278A4 (cg-RX-API-DMAC7.html)
JP (2) JP6193230B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140076551A (cg-RX-API-DMAC7.html)
CN (2) CN107903173A (cg-RX-API-DMAC7.html)
AR (1) AR087468A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012293157A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002712A8 (cg-RX-API-DMAC7.html)
CA (1) CA2842455A1 (cg-RX-API-DMAC7.html)
HK (1) HK1252353A1 (cg-RX-API-DMAC7.html)
IL (2) IL230552A (cg-RX-API-DMAC7.html)
MX (1) MX359697B (cg-RX-API-DMAC7.html)
NZ (1) NZ620300A (cg-RX-API-DMAC7.html)
RU (1) RU2648474C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201606442QA (cg-RX-API-DMAC7.html)
TW (2) TWI619498B (cg-RX-API-DMAC7.html)
WO (1) WO2013022079A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400707B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450128B (zh) * 2013-08-15 2015-04-08 河南中帅医药科技股份有限公司 用于治疗青光眼的前列腺素类似物中间体Corey醛的制备方法
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0455264B1 (en) * 1987-09-18 1994-07-13 R-Tech Ueno Ltd. Ocular hypotensive agents
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (cg-RX-API-DMAC7.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
AU2006209072B2 (en) * 2005-01-27 2011-02-24 Sucampo Ag Method and composition for treating central nervous system disorders
DE602006018583D1 (de) * 2005-03-04 2011-01-13 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US7211703B2 (en) * 2005-04-27 2007-05-01 Calgon Carbon Corporation Method of separating E and Z isomers of an alkene alcohol and derivatives thereof
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
MX339727B (es) * 2007-07-19 2016-06-06 R-Tech Ueno Ltd Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto.
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. Kaiya, "Prostaglandin E1 treatment of schizophrenia", Biological Psychiatry, 1984, 19(3): 457-463. *

Also Published As

Publication number Publication date
US20130035393A1 (en) 2013-02-07
TW201808302A (zh) 2018-03-16
RU2648474C2 (ru) 2018-03-26
AU2017203092B2 (en) 2018-11-08
IL230552A0 (en) 2014-03-31
CN107903173A (zh) 2018-04-13
EP2739278A4 (en) 2015-03-18
IL230552A (en) 2017-09-28
HK1252353A1 (zh) 2019-05-24
CA2842455A1 (en) 2013-02-14
MX2014001409A (es) 2014-05-28
AU2012293157A1 (en) 2014-03-13
BR112014002712A2 (pt) 2017-06-13
KR20140076551A (ko) 2014-06-20
BR112014002712A8 (pt) 2017-06-20
EP2739278A1 (en) 2014-06-11
IL254289A0 (en) 2017-10-31
US20140031428A1 (en) 2014-01-30
ZA201400707B (en) 2014-11-26
NZ620300A (en) 2015-09-25
JP2014527048A (ja) 2014-10-09
TW201316992A (zh) 2013-05-01
AR087468A1 (es) 2014-03-26
US8592483B2 (en) 2013-11-26
MX359697B (es) 2018-10-08
AU2017203092A1 (en) 2017-06-01
SG10201606442QA (en) 2016-09-29
JP2017222708A (ja) 2017-12-21
CN103841966A (zh) 2014-06-04
JP6193230B2 (ja) 2017-09-06
WO2013022079A1 (en) 2013-02-14
RU2014108423A (ru) 2015-09-10
TWI619497B (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
EP0435443B1 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
US5252605A (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
CA2046069C (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5302617A (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
CA2502439C (en) Prostaglandin compounds for the treatment of obesity
TWI619498B (zh) 精神分裂症的處置方法
KR20070107065A (ko) 중추 신경계 질환 치료를 위한 방법 및 조성물
EP0454429B1 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
US20080207759A1 (en) Method for protecting mitochondria
KR20080012407A (ko) 고안압증 및 녹내장 치료용 조성물
TWI594751B (zh) 治療帶有腹瀉之腸躁症之方法
HK1196278A (en) Method for treating schizophrenia
WO2016067620A1 (en) Method and composition for treating nonerosive reflux disease
JP2014515004A (ja) イオン輸送体の調節方法
ZA200207140B (en) Treatment of ocular hypertension and glaucoma.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees